All In Biotech

Investigational drug · Phase 3

divozilimab

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neuromyelitis Optica Spectrum Disorders, Systemic Scleroderma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "divozilimab"

First trial start

2022

Dec 12, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "divozilimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neuromyelitis Optica Spectrum Disorders
  • Systemic Scleroderma

Largest trials

Live from ClinicalTrials.gov: studies naming "divozilimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 10 on PubMed

Also in development for Neuromyelitis Optica Spectrum Disorders

  • GlucocorticoidsPhase 37 trials

    Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease

  • B001Phase 31 trial

    Shanghai Jiaolian Drug Research and Development Co., Ltd · Neuromyelitis Optica Spectrum Disorders

  • JYP0061Experimental Drug GroupPhase 22 trials

    Guangzhou JOYO Pharma Co., Ltd · Moderate-to-severe Atopic Dermatitis, Neuromyelitis Optica Spectrum Disorders

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.